Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
ADP-ribosyl Cyclase 1
/ immunology
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ immunology
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
/ immunology
Antineoplastic Combined Chemotherapy Protocols
/ immunology
Cohort Studies
Female
Humans
Immunologic Factors
/ immunology
Immunotherapy
/ methods
Male
Membrane Glycoproteins
/ immunology
Middle Aged
Multiple Myeloma
/ immunology
Progression-Free Survival
Proteasome Inhibitors
/ immunology
Young Adult
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
23
12
2018
accepted:
25
02
2019
revised:
17
02
2019
pubmed:
13
3
2019
medline:
6
2
2020
entrez:
13
3
2019
Statut:
ppublish
Résumé
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T
Identifiants
pubmed: 30858549
doi: 10.1038/s41375-019-0435-7
pii: 10.1038/s41375-019-0435-7
pmc: PMC6820050
mid: NIHMS1052954
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Immunologic Factors
0
Membrane Glycoproteins
0
Proteasome Inhibitors
0
daratumumab
4Z63YK6E0E
CD38 protein, human
EC 3.2.2.5
ADP-ribosyl Cyclase 1
EC 3.2.2.6
isatuximab
R30772KCU0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2266-2275Subventions
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer. 2019 Sep 1;125(17):2991-3000
pubmed: 31090928
Blood. 2017 Sep 28;130(13):1507-1513
pubmed: 28747306
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Blood. 2017 Jun 22;129(25):3294-3303
pubmed: 28483761
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Leukemia. 2017 Nov;31(11):2443-2448
pubmed: 28620163
Lancet Oncol. 2018 Dec;19(12):1641-1653
pubmed: 30442502
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Blood. 2012 Aug 2;120(5):947-59
pubmed: 22645181
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514
Blood. 2017 Aug 24;130(8):974-981
pubmed: 28637662